Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China

被引：0

作者：

Yang, X. ^{[1
]}

Dong, X. ^{[2
]}

Liu, Y. ^{[3
]}

Jin, B. ^{[4
]}

Wang, J. ^{[5
]}

Wang, Y. ^{[6
]}

Zhang, Y. ^{[7
]}

Zhuo, M. ^{[1
]}

Zhao, J. ^{[1
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China

[4] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[5] Peoples Liberat Army Gen Hosp, PLA Sch Med, Dept Oncol, Beijing, Peoples R China

[6] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China

[7] 1 Hosp Shijiazhuang, Dept Oncol, Shijiazhuang, Hebei, Peoples R China

来源：

关键词：

ALK; NSCLC; Alectinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P84.15

引用

页码：S663 / S663

页数：1